The Usefulness of SPECT/CT in Sentinel Node Mapping of Early Stage Breast Cancer Patients Showing Negative or Equivocal Findings on Planar Scintigraphy

Document Type: Original Article


1 Pakistan Kidney and Liver Institute & Research Centre. Lahore. Pakistan.

2 Pakistan Kidney and Liver Institute & Research Centre. Lahore. Pakistan



Objective(s): This study sought to determine the diagnostic yield of SPECT/CT in localizing axillary sentinel lymph nodes (SLNs) in early breast cancer patients where planar scintigraphy (PS) was equivocal or negative.
Methods: Prospective analysis of early stage breast cancer patients with nonpalpable axillary nodes undergoing SLN localization prior to nodal sampling for axillary staging. PS findings were categorized as: Category A: non-visualization of SLN; Category B: unusual uptake location; Category C: equivocal uptake /
difficult interpretation. The K-coefficient of Cohen was used to evaluate the correlation between PS and SPECT/CT results. PS and SPECT/CT images were interpreted separately, and SLN identification on each of the modalities was correlated to BMI (Body mass index) and peroperative radio guided results.
Results: Between April 2015 and January 2017, 1028 early breast cancer cases underwent sentinel lymphoscintigraphy. Of total, 134 (13%) patients underwent SPECT/CT in addition to PS. All were females with mean age of 48.15 years (range: 26-82 years). Right sided in 68, left in 64 and 2 with bilateral carcinoma. By TNM classification: 49 (37%) T1, 78 (58%) T2 and 7 (5%) had DCIS/Paget’s disease. Overall SLNs were detected on both PS and SPECT/CT in 60% cases. Of category A (n=54); 35/54 (64%) SLN localized on SPECT/CT; 32 were level-I; 2 Level-II; 1 Level-III nodes. In 19, SLN was not localized. Of category B (n=18), 5 had prior lumpectomy, SPECT/CT localized tracer uptake to 17 level-I sentinel nodes, 3 level-II and level III / IMC in 9. Of category C (n=62), 29 had prior lumpectomy. SPECT/CT confirmed SLN in all the cases. Radio-guided surgery confirmed SPECT/CT results. The correlation between the two techniques was low (K=0.34). Where PS was negative; SPECT/CT localized nodes in statistically significant number of cases (P=0.01). PS identified SLN uptakes in 80/134 (60%) cases with a mean BMI of 21.6±4.8 kg/m2 while SPECT/CT detected ‘‘hot’’ nodes in 115/134 (86%) cases with a mean BMI of 29.6±5.6 kg/m2. For overweight/obese patients (n=59) (BMI>25 kg/m2), PS failed to identify SLNs in 49 and SPECT/CT failed to do so in 18 (P<0.001).
Conclusion: SPECT/CT has diagnostic yield and helps in precise SLN localization where planar imaging is negative or shows unusual site of uptake.


Main Subjects

1.Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):359-86.

2.Khokher S, Qureshi MU, Riaz M, Akhtar N, Saleem A. Clinicopathologic profile of breast cancer patients in Pakistan: ten years data of a local cancer hospital. Asian Pac J Cancer Prev. 2012;13(2):693-8.

3.yman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30):7703-20.

4.Verheuvel NC, Voogd AC, Tjan-Heijnen VC, Siesling S, Roumen RM. Different outcome in node-positive breast cancer patients found by axillary ultrasound or sentinel node procedure. Breast Cancer Res Treat. 2017;165(3):555-63.

5.Kraft O, Havel M. Sentinel lymph nodes and planar scintigraphy and SPECT/CT in various types of tumour. Estimation of some factors influencing detection success. Nucl Med Rev Cent East Eur. 2013;16(1):17-25.

6.Dickinson RL, Erwin WD, Stevens DM, Bidaut LM, Mar MV, Macapinlac HA, et al. Hybrid modality fusion of planar scintigram and CT topograms to localize sentinel lymph nodes in breast lymphoscintigraphy: Technical description and phantom studies. Int J Mol Imaging. 2011;2011:298102.

7.Vidal-Sicart S, Valdes Olmos R. Sentinel node mapping for breast cancer: current situation. J Oncol. 012;2012:361341.

8.Canavese G, Bruzzi P, Catturich A, Tomei D, Carli F, Garrone E, et al. sentinel lymph node biopsy versus axillary dissection in node-negative early-stage breast cancer: 15-year follow-up update of a randomized clinical trial. Ann Surg Oncol. 2016;23(8):2494-500.

9.Jimenez-Heffernan A, Ellmann A, Sado H, Huić D, Bal C, Parameswaran R, et al. Results of a prospective multicenter international atomic energy agency sentinel node trial on the value of SPECT/CT over planar imaging in various malignancies. J Nucl Med. 2015;56(9):1338-44.

10. Van der Ploeg IM, Valdés Olmos RA, Nieweg OE, Rutgers EJ, Kroon BB, Hoefnagel CA. The additional value of SPETCT/TC in lymphatic mapping in breast cancer and melanoma. J Nucl Med. 2007;48(11):1756-60.

11. Kraft O, Havel M. Sentinel lymph node identification in breast cancer–comparison of planar scintigraphy and SPECT/CT. Open Nucl Med J. 2012;4:5-13.

12. van der Ploeg IM, Nieweg OE, Kroon BB, Rutgers EJ, Baas-Vrancken Peeters MJ, Vogel WV, et al. The yield of SPECT/CT for anatomical lymphatic mapping in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2009;36(6):903-9.

13. Olmos RV, Rietbergen DD, Vidal-Sicart S, Manca G, Giammarile F, Mariani G. Contribution of SPECT/CT imaging to radioguided sentinel lymph node biopsy in breast cancer, melanoma, and other solid cancers: from “open and see” to “see and open”. Q J Nucl Med Mol Imaging. 2014;58:127-39.

14. van der Ploeg IM, Valdés Olmos RA, Kroon BB, Nieweg OE. The hybrid SPECT/CT as an additional lymphatic mapping tool in patients with breast cancer. World J Surg. 2008;32(9):1930-4.

15. Lerman H, Lievshitz G, Zak O, Metser U, Schneebaum S, Even-Sapir E. Improved sentinel lymph node identification by SPECT/CT in overweight patients with breast cancer. J Nucl Med. 2007;48(2):201-6.

16. Lerman H, Metser U, Lievshitz G, Sperber F, Shneebaum S, Even-Sapir E. Lymphoscintigraphic sentinel node identification in patients with breast cancer: the role of SPECT-CT. Eur J Nucl Med Mol Imaging. 2006;33(3):329-37.

17. Martínez A, Zerdoud S, Mery E, Bouissou E, Ferron G, Querleu D. Hybrid imaging by SPECT/CT for sentinel lymph node detection in patients with cancer of the uterine cervix. Gynecol Oncol. 2010;119(3):431-5.

18. Vercellino L, Ohnona J, Groheux D, Slama A, Colletti PM, Chondrogiannis S, et al. Role of SPECT/CT in sentinel lymph node detection in patients with breast cancer. Clin Nucl Med. 2014;39(5):431-6.

19. U.S. breast cancer statistics. Available at: URL:; 2018.

20. Schneebaum S, Even-Sapir E, Lerman H, Gat A, Brazovsky E, Lievshitz G. Clinical application of gamma detection probes: radio guided surgery. Eur J Nucl Med. 1999;26(1):26-35.

21. Cox CE, Dupont E, Whitehead GF, Ebert MD, Nguyen K, Peltz ES, et al. Age and body mass index may increase the chance of failure in sentinel lymph node biopsy for women with breast cancer. Breast J. 2002;8(2):88-91.

22. Abdollahi A, Jangjoo A, Dabbagh Kakhki VR, Rasoul Zakavi S, Memar B, Naser Forghani M, et al. Factors affecting sentinel lymph node detection failure in breast cancer patients using intradermal injection of the tracer. Rev Esp Med Nucl. 2010;29(2):73-7.

23. Leijte JA, Van der Ploeg IM, Valdes Olmos RA, Nieweg OE, Horenblas S. Visualization of tumor blockage and rerouting of lymphatic drainage in penile cancer patients by use of SPECT/CT. J Nucl Med. 2009;50(3):364-7.

24. Schrenk P, Rehberger W, Shamiyeh A, Wayand W. Sentinel node biopsy for breast cancer: does the number of sentinel nodes removed have an impact on the accuracy of finding a positive node? J Surg Oncol. 2002;80(3):130-6.

25. Heuser T, Rink T, Weller E, Fitz H, Zippel HH, Kreienberg R, et al. Impact of the axillary nodal status on sentinel node mapping in breast cancer and its relevance for technical proceeding. Breast Cancer Res Treat. 2001;67(2):125-32.

26. Lo YF, Hsueh S, Ma SY, Chen SC, Chen MF. Clinical relevance of nonvisualized sentinel lymph nodes in unselected breast cancer patients during lymphoscintigraphy. Chang Gung Med J. 2005;28(6):378-86.

27. Kroon BK, Valdés Olmos R, Nieweg OE, Horenblas S. Non-visualization of sentinel lymph nodes in penile carcinoma. Eur J Nucl Med Mol Imaging. 2005;32(9):1096-9.

28. Bennie G, Vorster M, Buscombe J, Sathekge M. The added value of a single-photon emission computed tomography: computed tomography in the sentinel lymph node mapping in patients with breast cancer and malignant melanoma. World J Nucl Med. 2015;14(1):41-6.

29. Husarik DB, Steinert HC. Single photon emission computed tomogrsphy/computed tomography for sentinel node mapping in breast cancer. Semin Nucl Med. 2007;37(1):29-33.

30. Gallowitsch HJ, Kraschl P, Igerc I, Hussein T, Kresnik E, Mikosch P, et al. Sentinel node SPECT/CT in breast cancer. Can we expect any additional and relevant clinical information? Nuklearmedizin. 2007;46(6):252-6. 

31. Frusciante V, Niccoli A, Castriotta G, Guerra M, Murgo R, Ciuffreda L, et al. Added value of SPECT/CT over planar imaging in improving sentinel node detection in breast cancer patients. Recent Prog Med. 2016;107(8):444-9.

32. Keidar Z, Israel O, Krausz Y. SPECT/CT in tumor imaging: Technical aspects and clinical applications. Semin Nucl Med. 2003;33(3):205-18.

33. Law M, Ma WH, Leung R, Li S, Wong KK, Ho WY, et al. Evaluation of patient effective dose from sentinel lymph node lymphoscintigraphy in breast cancer: a phantom study with SPECT/CT and ICRP-103 recommendations. Eur J Radio. 2012;81(5):717-20.